Ipamorelin’s amino acid sequence at skyhighpeptides

The five-residue sequence

Ipamorelin’s sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. The original characterization describes this synthetic pentapeptide: five amino-acid residues in a chain. Aib is alpha-aminoisobutyric acid; the unusual residues help resist enzymatic breakdown.

The molecule was derived from GHRP-1 by removing its central Ala-Trp pair. I enjoy that molecular edit: shortening a chain helped produce a distinctive pattern of hormone release. The sequence identifies the molecule, while acetate identifies a salt form. Neither name supplies a clinical result.

Ipamorelin activates GHS-R1a, the ghrelin receptor. Its pituitary target overlaps with the growth hormone story of sermorelin, but the receptor differs. Ghrelin-related signalling also reaches appetite and the digestive tract, which helps explain why this molecule’s research wandered well beyond muscle claims.

Acute selectivity experiments

In rat pituitary cells, anaesthetised rats and conscious swine, ipamorelin released growth hormone strongly while ACTH and cortisol stayed no higher than the response to GHRH. This was an acute pharmacology result, and it distinguished ipamorelin from earlier growth hormone secretagogues.

Giving it the much broader meaning of safe, however, asks a brief experiment to answer questions it never addressed. These particular hormone measurements describe which signals rose during a brief test. Heart function, blood sugar and long-term tumour effects require their own investigation.

Intravenous studies in men and surgical patients

A pharmacokinetic study in healthy male volunteers used intravenous infusions, with eight men at each of five dose levels. Growth hormone peaked at about 40 minutes; ipamorelin’s terminal half-life was approximately 2 hours. Those are measurements of drug exposure and hormone response.

The later trial in 114 adults after bowel resection asked a practical question: could patients tolerate a meal sooner? It missed its primary endpoint. Treatment lasted up to seven days and went through a vein, under study supervision. Adverse events occurred in both groups.

The destination still surprises me. A compound best known online for growth hormone reached a hospital trial about eating after surgery. That trial gives the human record a clinical question and an unsuccessful primary result; it supplies no demonstrated benefit for sleep, strength or healthy aging.

Rat bones; ferret weight

Adult female rats in a 15-day bone-growth experiment had faster longitudinal bone growth without a measurable rise in total circulating IGF-1. Bone turnover markers were unchanged. The complication delights me: a tissue response can occur without the expected higher IGF-1 result in blood.

In ferrets given cisplatin, ipamorelin reduced chemotherapy-associated weight loss by approximately 24% on the last day of the delayed phase. Vomiting persisted. Anamorelin, a different compound delivered into the brain, reduced acute vomiting by 60% in that experiment.

The species, illness and outcome matter here. These animals supplied findings about bone length and preserving weight during illness. The studies leave ordinary adult fat-loss and recovery claims untested.

Heart, glucose and long-term exposure

A safety experiment with a different ghrelin-receptor agonist found heart-muscle degeneration and necrosis in rats. The compound was GSK894281; ipamorelin was not tested. This is a reason to investigate a receptor-class concern, with the distinction between the molecules intact. No equivalent long-duration cardiovascular study establishes ipamorelin’s safety.

Growth hormone can reduce insulin sensitivity, and the secretagogue review identifies higher blood glucose as an important class concern. Sustained growth hormone and IGF-1 exposure also raises a mechanistic question about existing tumours. Ipamorelin-specific human studies have not measured a long-term cancer risk.

Community descriptions of deeper sleep, vivid dreams and less soreness are anecdotal accounts, not clinical evidence. Flushing, hunger, puffiness, tingling, dizziness and local irritation appear in those accounts too. The material and other changes in people’s lives were unverified. I take the favourable and unfavourable reports with the same reservation.

FDA and sport status

Ipamorelin has never been approved as a medicine by any regulatory authority. On FDA’s page current as of April 22, 2026, the 503A nomination is listed as withdrawn. FDA supplies no withdrawal date. Taking back a nomination provides no ingredient clearance or drug approval.

Ipamorelin acetate remains in Category 2 under the 503B interim policy, which concerns larger outsourcing facilities and flags significant safety risks. The advisory committee reviewed ipamorelin in October 2024. A prescription alone does not establish a lawful compounding basis.

WADA prohibits ipamorelin in sport at all times. The combination page follows the separate question of pairing it with CJC-1295; the fixed combination lacks a controlled human trial.